Mapi Group Acquires Select Services of Optum Life Sciences

January 5, 2015

Applied Clinical Trials

Mapi has completed the acquisition of select Optum Life Sciences services.

Mapi, a Health Research and Commercialization services company, has completed the acquisition of select Optum Life Sciences services, including North American and European Regulatory Consulting, Late Phase CRO and European Health Economics and Outcomes Research (HEOR) teams. With the addition of these new services and experts, Mapi expands its experts covering the Americas, Europe, and Asia Pacific with additional expertise in Strategic Regulatory Services, Epidemiology, Strategic Market Access, Health Economics Outcomes Research, Patient Centered Outcomes, Language Services, Patient Insights, Direct to Patient Support and Real-World Evidence. 

 

Read the full release here.

Related Content:

News